Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TNXP with free AI briefings, catalyst countdowns, and dilution alerts.

TNXP · Tonix Pharmaceuticals Holding Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 11.7 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Nov 21, 2025, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$162.8M Cash on Hand
11.7mo Cash Runway
Follow TNXP by email Get an email when TNXP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TNXP, unsubscribe in one click. Privacy

📣 What TNXP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cyclobenzaprine
FDA approved Aug 2025 · Tonmya
Primary Fibromyalgia Phase 3 · NCT02589275 Completed
TNX-102 SL Fibromyalgia Phase 3 · NCT05273749 Completed
Isometheptene Mucate Tension-Type Headache Phase 2 · NCT02423408 Completed
TNX-1300 Cocaine Intoxication Phase 2 · NCT04996056 Withdrawn
Cocaine Esterase Cocaine Use Phase 2 · NCT06045793 Terminated
TNX-1500 Kidney Transplant Phase 2 · NCT07204080 Not yet recruiting
TNX-1900 Chronic Migraine Phase 2 · NCT05679908 Completed
Oxytocin Pain Phase 2 · NCT07730294 Recruiting
Tianeptine Depression Phase 2 · NCT05686408 Completed
TNX-201 Healthy Phase 1 · NCT02290379 Completed
TNX-2110 Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in… Phase 1 · NCT05216510 Terminated
TNX-102-C SL Tablets at 2.8 mg Healthy Adults Phase 1 · NCT01889173 Completed
TNX-2120 Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in… Phase 1 · NCT05216510 Terminated
TNX-2130 Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in… Phase 1 · NCT05216510 Terminated
TNX-102-B SL Tablets at 2.8 mg Healthy Adults Phase 1 · NCT01889173 Completed
Intranasal Oxytocin (IN-OXT) 24 IU single dose Vasopressin Deficiency Phase 1 · NCT04789148 Recruiting

Also used in these trials (approved or third-party drugs, not TNXP's own candidates): Cyclobenzaprine Hcl, Treprostinil.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TNXP holds $162.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $41.7M/quarter from operations, an estimated runway of 11.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TNXP files for a raise →

👥 Who Owns TNXP

Insiders 0.2% Other 5%+ holders 10.2% Institutions (148 holders) 57% Public and other holders 32.6%
HolderTypeShares% of sharesAs of
Point72 Asset Management, L.P. 5%+ holder (13G) 1,100,964 5.67% 2026-03-31
Millennium Management LLC 5%+ holder (13G) 890,366 4.58% 2026-06-09
BlackRock, Inc. Institution (13G, 5%+) 854,579 4.40% 2025-12-31
Seth Lederman
Chief Executive Officer, Director · +269,007 options
Insider 36,007 0.19% 2026-11-11
Richard Newcomb Stillwell
Director · +32,700 options
Insider 5,000 0.03% 2026-06-08
Bradley Saenger
Chief Financial Officer · +129,607 options
Insider 2,154 0.01% 2026-06-30
Carolyn E. Taylor
Director · +32,700 options
Insider 1,833 0.01% 2026-06-12
Richard H Bagger
Director · +32,700 options
Insider 1,000 0.01% 2026-08-20
Thomas Englese
Chief Commercial Officer
Insider 694 0.00% 2026-09-04
James Treco
Director · +32,700 options
Insider 250 0.00% 2025-08-20

Share count 19,431,516 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-08-15 Tonmya™ NDA +32.2% -13.8% -39.8%

Browse all historical PDUFA outcomes →

Get the full TNXP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TNXP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.